MOQIPEOPLE INSIDER:
iBreastExam (iBE), A Unique Detection Device with FDA Approved for an Early Breast Tumor – Now is Available for Commercial Use in the USA and India.
iBreastExam (iBE) is a quick and convenient breast health check. It is an early indication test like blood pressure monitor, glucometer or pulse oximeter. iBreastExam can be made available to women in the privacy and comfort of their home. HR managers can organize breast health camps in the office premises and governmental health agencies can make early detection accessible to women around the world.
iBreastExam (iBE) Received US FDA 510k Clearance as ” Breast Lesion Documentation System” since April 2015. iBreastExam (iBE) now is available for commercial use in the USA and India.
iBreastExam™ (or iBE) is a game-changing technological breakthrough for countries and regions with rising incidence of breast cancer, most cases presenting at late stages and limited to no access to early detection for most women. iBreastExam™ harnesses the power of innovative sensor technology, software computing and mobile revolution, such that a doctor or any health-worker can offer objective and effective breast examinations, with ease and comfort.
iBE™ Quick Facts
- Bilateral breast exam within 5 minutes (with results at the point-of-care)
- Accuracy to detect clinically relevant breast lesions higher than 85%
- Usable by any health-worker or doctor. No pain, No radiation.
*iBE™ is developed by the makers of NoTouch BreastScan™.
iBE™ was originally invented at Drexel University in Philadelphia, PA. iBE™’s sensor technology accurately assesses & identifies tissue elasticity differences between hard & stiff breast cancer tumors versus normal, benign breast tissue. The patented tactile sensor technology using Piezoelectric Sensor Array, invented by the scientists and doctors at Drexel University is a novel, quantitative and low-cost elastic modulus (E) and shear modulus (G) sensor that can measure tissue compression and shear stiffness either by top down or lateral touching of the skin surface. iBE™’s ability to apply a force and measure the displacement electrically, all within the sensor, makes for an ideal ‘electronic palpation’ sensor for in-vivo breast imaging.
Translational research and commercialization of iBreastExam innovation is backed by R&D funding from Drexel University, Coulter Foundation, University City Science Center’s QED and DHA Program, Pennsylvania Department of Health’s CURE Grant and Unitus Seed Fund’s StartHealth Program.
Read more info via:
http://www.ibreastexam.com
http://www.notouchbreastscan.com/about.html
